Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab + SOC in mCRC, mGEC, and mRCC
NCT03798626Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 1, open-label trial of gevokizumab in colorectal cancer (CRC), gastroesophageal junction cancer and renal cell carcinoma (RCC) (4 cohorts), sponsored by Novartis. Primary endpoints: Change in high-sensitivity C-reactive protein at Day 15, Number of dose limiting toxicities at 6 weeks and 1 more. Started May 2019; status: completed.
02
Drugs
gevokizumab
03
Conditions
colorectal cancer (CRC)gastroesophageal junction cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03798626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798626.